Abbott Laboratories to Submit Limb-Threatening Ischemia Drug to FDA Review

By Sabela Ojea

Abbott Laboratories said it has received positive results from its chronic limb-threatening ischemia trial and it expects to submit the drug for review by the U.S. Food and Drug Administration.

The medical devices and health care company on Wednesday said the trial met both primary safety and effectiveness endpoints and showed that its Esprit BTK drug reduces disease progression.

Chronic limb-threatening ischemia is a form peripheral arterial disease, which causes an accumulation of plaque in the arteries in legs or arms.

About 22 million people worldwide have been affected by chronic limb-threatening ischemia.

Write to Sabela Ojea at [e-mail]

(END) Dow Jones Newswires

10-25-23 1502ET